Share Awards

RNS Number:8963T
Napo Pharmaceuticals Inc
07 May 2008


For immediate release                                               7 May 2008

                            Napo Pharmaceuticals Inc.
                            ("Napo" or "the Company")

    NOTIFICATON OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL
                      RESPONSIBILITY OR CONNECTED PERSONS

South San Francisco, California, 7 May 2008 - Napo Pharmaceuticals, Inc.
("Napo") (LSE: NAPL and NAPU) provides below details of changes in the interests
of Persons Discharging Managerial Responsibility or Connected Persons in the
Ordinary Shares of Napo Pharmaceuticals, Inc.

On 1 May, 2008, the individuals listed in the table below were granted at par
value, outside of Napo's equity incentive plans, an aggregate of 1,300,000
restricted stock awards for the Company's common stock. These restricted stock
awards are part of an aggregate of 2,415,000 restricted stock awards granted on
the same date by Napo, outside of its equity incentive plans, to employees,
consultants and the board of directors.

The restricted stock awards are over shares in the Company's Regulation S line
of stock (NAPL; ISIN USU629901039)

The CEO of Napo, Lisa A. Conte and the CFO of Napo, Charles Thompson, declined
their awards.

Lisa A. Conte, CEO of Napo Pharmaceuticals, Inc. commented: "The grants approved
by the board of directors are a critical element in maintaining our momentum and
aligning the interests of shareholders, employees and board members to achieve
our number one goal - an approved NDA for crofelemer and value recognition of
our achievements to benefit our shareholders. The retention and motivation of
our team is essential to reaching this goal."

The restricted stock awards described in this notification place restrictions on
the named individual's rights over the common stock, such as the inability to
transfer the stock and the risk of forfeiture, until one of the following
criteria is met: i) an NDA approval for crofelemer; ii) Napo common stock
reaching a price per share of US$3.50 or iii) a change of control. The
restricted stock awards will expire at the end of 36 months from the date of
grant if the criteria for release of restrictions on the stock are not met.

Name        Role                  Number of  Amount   Criteria for Release of
                                  Restricted Paid up  Restrictions on the
                                  Shares     at Par   Stock
Pravin
Chaturvedi,
Ph.D.       President and Chief    150,000    #7.62   Upon NDA approval for
            Scientific Officer                        crofelemer or US$.3.50
                                                      Napo stock price or a
                                                      change of control
Steven R.
King, Ph.D. Vice-President         150,000    #7.62   Upon NDA approval for
            Ethnobotanical                            crofelemer or US$.3.50
            Research, Sustainable                     Napo stock price or a
            Supply and IP                             change of control
Sir William
Young       Non-Executive          250,000   #12.70   Upon NDA approval for
            Director                                  crofelemer or US$.3.50
                                                      Napo stock price or a
                                                      change of control
Jack Van    Non-Executive          250,000   #12.70   Upon NDA approval for
Hulst       Director                                  crofelemer or US$.3.50
                                                      Napo stock price or a
                                                      change of control
Dr. Gregory
Stock       Non-Executive          250,000   #12.70   Upon NDA approval for
            Director                                  crofelemer or US$.3.50
                                                      Napo stock price or a
                                                      change of control
Thomas Van
Dyck        Non-Executive          250,000   #12.70   Upon NDA approval for
            Director                                  crofelemer or US$.3.50
                                                      Napo stock price or a
                                                      change of control

This notification relates to a transaction notified in accordance with
Disclosure Rule 3.1.4R(1)(a).

For more information please contact:

Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
[phone]

Charles Thompson, Chief Financial Officer
[phone]

Buchanan Communications
+ 44 (0)20 7466 5000
Tim Anderson, Mary-Jane Johnson


Napo Pharmaceuticals Inc., focuses on the development and commercialization of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India. Napo's late-stage proprietary
gastro-intestinal compound, crofelemer, is in various stages of clinical
development for four distinct product indications, including a late-stage Phase
3 program:

   *CRO-HIV for AIDS diarrhea, Phase 3
   *CRO-IBS for diarrhea irritable bowel syndrome (D-IBS), Phase 2
   *CRO-ID for acute infectious diarrhea (including cholera), Phase 2
   *CRO-PED for pediatric diarrhea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV. Crofelemer, a
proprietary patented agent, is extracted from Croton lechleri, a medicinal plant
which can be sustainably harvested from several countries in South America. Napo
also plans to develop an early clinical stage product, NP-500, for the treatment
of insulin resistant diseases of Type II diabetes and metabolic syndrome
(Syndrome X; pre-diabetic syndrome). Napo also has a plant library of
approximately 2,300 medicinal plants from tropical regions and Napo has entered
its first screening relationship associated with this collection. Currently,
products are based on the chemical and biological diversity derived from plants
with medicinal properties, but future products may be in-licensed from other
sources. Napo has partnerships with Glenmark Pharmaceuticals Limited of India
and AsiaPharm Group Ltd. of China. For more information please visit
www.napopharma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSKGGGKFNGGRZM